Specialized in 3D cell culture assays and models, 3D tissue imaging, and digital pathology, Visikol is organized around accelerating drug discovery through quantitative histopathology and using the firm's patented Visikol® HISTO tissue clearing technology to transform tissues into three dimensional data sets that can be mined for actionable insights. Exclusively licensed from Rutgers, when paired with fluorescent labeling and 3D microscopy, Visikol® HISTO allows tissues such as 3D cell culture models or whole tissues to be imaged in their entirety in 3D. Visikol has leveraged this technology to launch 3Screen which is a high-throughput 3D imaging platform capable of transforming tissues into 3D data sets and answering complex biological questions. The addition of 3D histological information to the drug discovery workflow allows for complex features such as vasculature networks to be quantitatively analyzed in 3D or for the penetration kinetics of antibodies into tumor models to be understood. The company currently offers 3Screen as a service to pharmaceutical/biotech companies and is continually focused on improving the platform as well as building out a suite of standardized assays. In addition to this service offering, Visikol also sells various tissue clearing reagents and kits for academic researchers that are interested in adopting the approach into their own workflows. In May 2021, it was announced that Visikol had been acquired fot $7.5M by Sweden-based CELLINK - CELLINK -- a bioconvergence company.
